Irinotecan liposome II combination therapy is named as an intervention in 2 current clinical trials in our China register. 2 are recruiting patients now. The most common phase is Observational. The sponsor with the most trials is Peking Union Medical College Hospital (1). The most-studied condition is Pancreatic Cancer.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Irinotecan Liposomes Combined with Epirubicin in Recurrent Non-muscle Invasive Bladder Urothelium Carcinoma After Anthracyclines Treatment
NCT06766266 · ClinicalTrials.gov ↗ · Non-Muscle Invasive Bladder Urothelial Carcinoma
|
Phase 1 | Recruiting | First Affiliated Hospital of Chongqing Medical University | China |
|
Treatment of Irinotecan Hydrochloride Liposome Injection II in China: a Real World Study of Pancreatic Cancer Patients
NCT06375473 · ClinicalTrials.gov ↗ · Pancreatic Cancer
|
Observational | Recruiting | Peking Union Medical College Hospital | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Peking Union Medical College Hospital | 1 |
| First Affiliated Hospital of Chongqing Medical University | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 2 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our China register name Irinotecan liposome II combination therapy as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 2 trials are recruiting: 2 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Peking Union Medical College Hospital (1) and First Affiliated Hospital of Chongqing Medical University (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Irinotecan liposome II combination therapy works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Irinotecan liposome II combination therapy works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Irinotecan liposome II combination therapy (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.